JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.
🌐 JAMAOncology.com
JAMA Oncology
Loading...
A 58-year-old woman with #BreastCancer with multiple prior courses of systemic treatments presented with hypotension, hypoxia, significant polyuria, and polydipsia. Mild thickening of the pituitary stalk was seen.
✍️ What is your diagnosis? ja.ma/4vAqpXs
This Special Communication provides consensus recommendations on the acquisition, interpretation, and reporting of prostate magnetic resonance imaging for cancer screening. ja.ma/4eApoJc
Avelumab combined with methotrexate resulted in >95% durable remission and preserved #fertility in low-risk gestational trophoblastic #tumors, with a manageable safety profile.
ja.ma/3RRcFcp
Sequential radiotherapy and immunotherapy (#iRT) provided longer overall survival than concurrent iRT for newly diagnosed advanced non–small cell lung cancer, with additional benefit from chemotherapy.
ja.ma/4oe1whI
Among patients with early age–onset #ColorectalCancer in Texas, treatment delays longer than six weeks were associated with reduced survival, and language barriers represented a major risk factor contributing to delayed initiation of definitive therapy. ja.ma/3S1igN7
Sequential radiotherapy and immunotherapy (#iRT) provided longer overall survival than concurrent iRT for newly diagnosed advanced non–small cell lung cancer, with additional benefit from chemotherapy.
ja.ma/4dRk9EG
A phase 3 trial shows serplulimab plus chemotherapy improved overall survival and 4-year survival rates vs chemotherapy alone in extensive-stage small cell #LungCancer, with durable benefit and manageable safety. ja.ma/4x4hcrO
A meta-analysis found first-line chemoimmunotherapy provided longer overall and progression-free survival than PD-(L)1 inhibitor monotherapy in advanced #NSCLC with high #PDL1, though with greater toxicity. ja.ma/43Nj4aU
Oral upadacitinib achieved rapid resolution and pruritus relief in severe immune checkpoint inhibitor–related #Dermatitis, with no serious treatment-related adverse events.
ja.ma/4vAMjdf
From @jama.com: In resected non-small cell lung #cancer, adjuvant #nivolumab following standard care was not associated with improved survival or recurrence risk compared with observation, even in tumors with high PD-L1 expression.
#ASCO26 @ascocancer.bsky.social
ja.ma/3RypEQ2
